Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Authors
Genestreti, GTiseo, M
Kenmotsu, H
Kazushige, W
Di Battista, M
Cavallo, G
Carloni, F
Bongiovanni, A
Burgio, M
Casanova, C
Metro, G
Scarpi, E
Korkmaz, T
Selcuk, S
Kurup, Roopa
Califano, Raffaele
Affiliation
Department of Medical Oncology, AUSL Bologna, ItalyIssue Date
2015-04-24
Metadata
Show full item recordAbstract
Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide.Citation
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. 2015: Clin Lung CancerJournal
Clinical Lung CancerDOI
10.1016/j.cllc.2015.04.006PubMed ID
25983005Type
ArticleLanguage
enISSN
1938-0690ae974a485f413a2113503eed53cd6c53
10.1016/j.cllc.2015.04.006